| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDE5A |
| Uniprot No | O76074 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 534-875aa |
| 氨基酸序列 | EEETRELQSLAAAVVPSAQTLKITDFSFSDFELSDLETALCTIRMFTDLNLVQNFQMKHEVLCRWILSVKKNYRKNVAYHNWRHAFNTAQCMFAALKAGKIQNKLTDLEILALLIAALSHDLDHRGVNNSYIQRSEHPLAQLYCHSIMEHHHFDQCLMILNSPGNQILSGLSIEEYKTTLKIIKQAILATDLALYIKRRGEFFELIRKNQFNLEDPHQKELFLAMLMTACDLSAITKPWPIQQRIAELVATEFFDQGDRERKELNIEPTDLMNREKKNKIPSMQVGFIDAICLQLYEALTHVSEDCFPLLDGCRKNRQKWQALAEQQEKMLINGESGQAKRN |
| 预测分子量 | 41.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 PDE5A 重组蛋白的3篇参考文献的简要列举：
---
1. **文献名称**: *"Crystal structure of the catalytic domain of phosphodiesterase 5A bound to sildenafil"*
**作者**: Francis SH et al.
**摘要**: 该研究解析了人源PDE5A催化结构域的晶体结构，并揭示了其与抑制剂西地那非(sildenafil)的结合模式，为药物设计提供了结构基础。
---
2. **文献名称**: *"Recombinant expression and functional characterization of human PDE5A: therapeutic implications for pulmonary hypertension"*
**作者**: Galie N et al.
**摘要**: 通过重组表达技术获得活性人源PDE5A蛋白，验证其酶活性和药物敏感性，并探讨其在肺动脉高压治疗中的作用机制。
---
3. **文献名称**: *"High-yield production of human PDE5A in Escherichia coli for biochemical and biophysical studies"*
**作者**: Wang H et al.
**摘要**: 提出一种高效的大肠杆菌表达系统，用于可溶性PDE5A重组蛋白的大规模制备，优化纯化流程以满足酶动力学和药物筛选需求。
---
4. **文献名称**: *"Engineering a thermostable PDE5A variant for enhanced cGMP hydrolysis activity"*
**作者**: Zhang Y et al.
**摘要**: 通过定向进化技术改造PDE5A重组蛋白，获得热稳定性与催化活性显著提升的突变体，为酶替代疗法提供潜在候选分子。
---
以上文献涵盖结构解析、治疗应用、表达优化及工程改造等方向，具体信息需结合实际数据库(如PubMed)检索确认。
PDE5A recombinant protein is a purified, biologically active form of the human phosphodiesterase type 5A enzyme, produced through genetic engineering techniques. PDE5A is a member of the cyclic nucleotide phosphodiesterase family that specifically hydrolyzes cyclic guanosine monophosphate (cGMP), a key secondary messenger regulating vascular smooth muscle relaxation, platelet aggregation, and neurotransmission. The enzyme gained prominence due to its role as the pharmacological target of sildenafil (Viagra®) and related drugs for erectile dysfunction and pulmonary arterial hypertension.
Native PDE5A contains conserved catalytic and regulatory domains. Recombinant versions are typically expressed in bacterial (e.g., E. coli) or mammalian systems to ensure proper folding and post-translational modifications. The protein retains enzymatic activity, enabling researchers to study its kinetic properties, inhibitor interactions, and structural features. Its production facilitates high-throughput screening of PDE5 inhibitors for drug development and mechanistic studies of cGMP signaling pathways.
Applications extend to cardiovascular research, neurological studies, and molecular modeling. Recombinant PDE5A is crucial for crystallography studies that revealed drug-binding pockets, aiding structure-based drug design. Quality-controlled batches ensure consistency in biochemical assays, overcoming variability issues from tissue-extracted enzymes. Current research also explores PDE5A isoforms (PDE5A1. A2. A3) with distinct tissue distributions and regulatory mechanisms. As a research tool, it contributes to understanding pathologies like hypertension, fibrosis, and neurodegenerative diseases linked to cGMP dysregulation.
×
